<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23193">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01664013</url>
  </required_header>
  <id_info>
    <org_study_id>MT_IT_010</org_study_id>
    <nct_id>NCT01664013</nct_id>
  </id_info>
  <brief_title>The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients</brief_title>
  <official_title>The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roongroj Bhidayasiri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the impact of botulinum toxin treatment in
      quality of life(QoL) in cervical dystonia patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To investigate the change of quality of life of cervical dystonia patients after botulinum toxin treatment measured by CDQ-24.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the change of quality of life of cervical dystonia patients from baseline at 6 weeks after botulinum toxin treatment measured by CDQ-24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the change of QoL of cervical dystonia patientsafter botulinum toxin treatment  measured by SF-36 (Thai version)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the change of QoL of cervical dystonia patients at 6weeks after botulinum toxin treatment from baseline measured by SF-36 (Thai version).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Investigate the change of symptom after botulinum toxin treatment  measured by TWSTRS score</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To Investigate the change of symptom at 6weeks after botulinum toxin treatment from baseline measured by TWSTRS score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Botulinum Toxin</condition>
  <condition>Quality of Life</condition>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Neuronox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nuronox</intervention_name>
    <description>Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.</description>
    <arm_group_label>Neuronox</arm_group_label>
    <other_name>Clostridium Botulinum Toxin A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged ≥ 18 years to 75 years

          -  Subjects requiring treatment for a clinical diagnosis of cervical dystonia

          -  Willing to provide written informed consent before any study-related procedures.

        Exclusion Criteria:

          -  Patients with pure anterocollis

          -  Patients with an anaphlyactic response history to botulinum toxin type A.

          -  Patients who have been treated with botulinum toxin type A within 3 month.

          -  Females who are pregnant, planning pregnancy, unable to use contraception or
             lactating.

          -  Any medical condition that may put the subject at increased risk with exposure to
             botulinum toxin at the discrimination of investigators.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roongroj Bhidayasiri, MD</last_name>
    <phone>+662 2564630</phone>
    <email>rbh1@ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roongroj Bhidayasiri</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roongroj Bhidayasiri, MD</last_name>
      <phone>+662 2564630</phone>
      <email>rbh1@ucla.du</email>
    </contact>
    <investigator>
      <last_name>Roongroj Bhidayasiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 18, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Roongroj Bhidayasiri</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
